- Wondering whether Hologic at around US$75.67 is still a sensible entry point or if the recent run has already priced in the opportunity? This breakdown will help you assess what you are really paying for.
- The stock has returned 0.3% over the last 7 days, 0.4% over 30 days, 1.5% year to date and 23.4% over the past year. The 3 year and 5 year returns of negative 6.2% and 1.8% show a mixed longer term picture around that recent strength.
- Recent price moves sit against a backdrop of ongoing attention on Hologic as a key medical equipment name, with investors weighing its role in diagnostics and women’s health against broader sector sentiment. News flow has tended to focus on how the company is positioned within healthcare demand trends and capital allocation decisions. This helps frame how the market currently thinks about its quality and risk profile.
- Right now Hologic scores a value rating of 3 out of 6 on Simply Wall St's valuation checks. The rest of this article will walk through what that means across different valuation approaches before finishing with a way to think about value that goes beyond the usual multiples and models.
Approach 1: Hologic Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today’s value. It is essentially asking what those future dollars are worth in today’s terms.
For Hologic, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $942.7 million, and analysts provide explicit forecasts out to 2028, with Simply Wall St extrapolating further to build a 10 year path. Within those projections, free cash flow used in the model reaches about $1.52b in 2035. All figures are kept in dollar terms and then discounted back to today.
Based on those cash flows, the DCF model arrives at an estimated intrinsic value of about $108.50 per share. Compared with a current share price of roughly $75.67, this indicates that, on this approach, Hologic is assessed as trading at around a 30.3% discount to the model’s estimated intrinsic value.
Result: UNDERVALUED on this DCF measure
Our Discounted Cash Flow (DCF) analysis suggests Hologic is undervalued by 30.3%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.
Approach 2: Hologic Price vs Earnings
For a profitable company like Hologic, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. A higher or lower P/E often reflects how the market views its growth prospects and risk profile, with faster growth or lower perceived risk usually supporting a higher “normal” multiple.
Hologic currently trades on a P/E of 31.06x. That sits above the broader Medical Equipment industry average of 27.18x, but below the peer group average of 47.07x. Simply Wall St’s “Fair Ratio” for Hologic is 30.86x. This is a proprietary estimate of what the P/E might reasonably be, given factors such as earnings growth, industry, profit margin, market cap and specific risks.
This Fair Ratio is more tailored than a simple comparison with industry or peers, because it adjusts for the company’s own characteristics rather than assuming all Medical Equipment names should trade at the same multiple. Hologic’s actual P/E of 31.06x is very close to the Fair Ratio of 30.86x. This suggests the shares are priced broadly in line with what this framework would imply.
Result: ABOUT RIGHT
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Hologic Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about Hologic to the numbers by linking what you believe about its diagnostics and women’s health business to a specific forecast for revenue, earnings and margins. You can then turn that into a Fair Value that you can compare with the current price to decide if it looks attractive or stretched. Each user’s Narrative can range from a more upbeat view that leans on the US$79 per share cash offer and expectations for higher margins, to a more cautious view that focuses on China headwinds, tariffs and the consensus Fair Value of about US$76.67. Narratives update automatically as new news or earnings arrive, and they are all available to explore and build on the Community page that millions of investors use.
Do you think there's more to the story for Hologic? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com